Gilead Sciences (NASDAQ: GILD) witnessed a notable 4% surge in its stock price this morning, driven by a confluence of encouraging developments in drug trials, a positive industry outlook, and growing...
Bristol Myers Squibb Company BMY touched a 52-week high of $56.8 on Nov. 6. The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months, regaining...
This week, we have Home Depot, Alibaba, Disney, Shopify and Spotify all set to report among some other important names.
High yields aren't a warning indicator with these three stocks.
/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.
Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.
Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth.
/CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) announced today that Paul Petrelli joined the organization as Vice President and General Manager. In his...
GILD earnings call for the period ending September 30, 2024.